Skip to content

Cytokinetics CYTK Other accrued liabilities

Other accrued liabilities at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$12.62B-23.6%
Boston Scientific logo
Boston ScientificBSX
$875M-5.2%
Eli Lilly logo
Eli LillyLLY
Merck & Co. logo
Merck & Co.MRK
Medtronic logo
MedtronicMDT

Other financials

Income statement

See full
Revenue$19.4M+1,126%
Operating income-$183.6M-18.0%
Net income-$206.0M-27.7%
EPS (diluted)-$1.67-22.8%

Balance sheet

See full
Cash & equivalents$129.8M+76.2%
Total debt$418.2M+75.8%
Total equity-$826.6M-210%
Total assets$1.3B+0.7%

Cash flow

See full
Operating cash flow-$145.5M-10.5%
CapEx$5.9M+4.7%
Free cash flow-$151.4M-10.3%

Valuation

See full
Market cap$10.7B+70.6%
Enterprise value$10.98B+70.7%
P/S101.1×-225×

Profitability

See full
Operating margin-605.1%-268pp
Net margin-784%-337pp
FCF margin-518.8%-223pp

Returns & leverage

See full
Return on equity-337.6%
Debt / equity2.2×
Current ratio4.2×-1.8×

Where this comes from

Reported directly by Cytokinetics in its filing.

Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.

The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cytokinetics's other accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cytokinetics's other accrued liabilities?
Cytokinetics (CYTK) reported other accrued liabilities of $8.59M in Q1 2026.
How has Cytokinetics's other accrued liabilities changed year-over-year?
Cytokinetics's other accrued liabilities increased by 47.6% year-over-year, from $5.82M to $8.59M.
What is the long-term trend for Cytokinetics's other accrued liabilities?
Over 5 years (2020 to 2025), Cytokinetics's other accrued liabilities has grown at a 29.6% compound annual growth rate (CAGR), from $1.05M to $3.83M.